Page 296 - ESHRE2019
P. 296

P-602 Cumulus cell-bound bone morphogenetic protein-15 varies with maternal age and PCO/S in ICSI patients
A. Krysta1,2, A.H. Riepsamen1, S. Kilani1,2, C.A. Harrison3, K.A. Mallitt1,4, W.L. Ledger1,2, D.M. Robertson1, R.B. Gilchrist1
1Fertility and Research Centre- School of Women’s and Children’s Health, University of New South Wales Sydney, Kensington- NSW, Australia
2IVF Australia, Virtus Health, Alexandria- NSW, Australia
3Monash Biomedicine Discovery Institute, Monash University, Clayton- NSW, Australia
4Centre for Big Data Research in Health, University of New South Wales Sydney, Kensington- NSW, Australia
P-603 BMI is not associated with oocyte recovery rate or maturation rate in high-risk for severe OHSS patients triggered with GnRH-agonist for final oocyte maturation
I. Sfontouris1, G. Lainas1, T. Lainas1, J. Bosdou2, A. Chatzimeletiou2, G. Grimbizis2, E. Kolibianakis2 1Eugonia, Assisted Reproduction Unit, Athens, Greece
2Aristotle University of Thessaloniki, Unit of Human reproduction- 1st Department of Ob/Gyn- Medical school, Thessaloniki, Greece
P-604 Intrauterine insemination (IUI) with or without letrozole for unexplained or mild male factor infertility: a randomized pilot study
S. Huang1, R. Wang2,3, R. Li1, H. Yan1, N. Li1, H. Wang1, L. Luo1, R.J. Norman2, B.W.J. Mol3, J. Qiao1
1Centre of Reproductive Medicine, Department of Obstetrics and Gynecology- Peking University Third Hospital, Beijing, China
2Robinson Research Institute, University of Adelaide, Adelaide, Australia
3Department of Obstetrics and Gynaecology, Monash Medical Centre- Monash Health and Monash University, Melbourne, Australia
P-605 Patients < 38 years old and diminished ovarian reserve: Qualitative reduction in IVF success?
J. Belaisch Allart1, O. Kulski1, L. Prevotat1, Y. Belaid1, J.M. Mayenga1, I. Grefenstette1, N. Kalhorpour1 1Gynecologie Obstétrique et Médecine de la Reproduction, Haut de Seine, Saint Cloud, France
P-606 Is oocyte maturation rate associated with the dose of triptorelin used for triggering final oocyte maturation in high-risk for severe OHSS patients, undergoing ovarian stimulation
T.G. Lainas1, G. Lainas1, I. Sfontouris1, C. Venetis2, J. Bosdou3, A. Chatzimeletiou3, B. Tarlatzis3, G. Grimbizis3, E. Kolibianakis3
1Eugonia, Unit of Assisted Reproduction, Athens, Greece
2University of New South Wales, School of Women’s and Children’s Health UNSW Medicine, Sydney, Australia
3Aristotle University of Thessaloniki Medical School, Unit for Human Reproduction - 1st Dept of Obstetrics and Gynecology, Thessaloniki, Greece
               296













































































   294   295   296   297   298